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Infection of dogs by Leishmania 
infantum elicits a general response 
of IgG subclasses
A. I. Olías‑Molero1, I. Moreno2, M. J. Corral1, M. D. Jiménez‑Antón1, M. J. Day3,4, 
M. Domínguez2 & J. M. Alunda1*
Leishmania infantum is the etiological agent of zoonotic visceral leishmaniasis. In endemic areas, 
canine infections are considered the main source of infection for human populations. Therefore, 
any control of human leishmaniasis must include the control of canine infections. Chemotherapy of 
leishmaniasis is inadequate and canine immunoprophylaxis has important limitations. Reports on the 
response of infected dogs are abundant but no clear picture of immune events has emerged. To shed 
some light on these shortcomings the specific IgG subclass response was followed in 20 Beagle dogs 
experimentally infected with L. infantum using monoclonal antibodies (MAb) specific for canine  IgG1, 
 IgG2,  IgG3 and  IgG4, along with ELISA and flow cytometry. Results showed that parasitic infection 
elicits a general response of all IgG subclasses, with a predominant  IgG1 response and without any 
evidence of  IgG1/IgG2 dichotomy. These findings suggest that the inconsistent results reported 
previously could be related to the lack of specific reagents and not to the actual differences in the 
immune response of infected animals. Differential IgG subclass reactivity in ELISA and cytometry and 
the analysis of the reacting antigens could facilitate the diagnosis and prognosis of the disease and 
provide a useful tool for adequate therapeutics and vaccine development against leishmaniasis.
Visceral leishmaniasis (VL) is a vector-borne parasitic disease caused by the infection with protozoa of the 
genus Leishmania. The disease is widely distributed and it is considered the second most lethal parasitic dis-
ease in humans, after  malaria1,2. Apparent expansion of VL has been  reported3,4 and some factors have been 
incriminated such as new epidemiological patterns, extensive human travel, and climate change, among  others5. 
Two species are mainly responsible for human visceral infections: L. donovani and L. infantum (= L. chagasi). 
There are some reports on L. donovani infections in non-human hosts although its transmission cycle is mainly 
anthroponotic. However, L. infantum, prevalent in Asia, South America and southern Europe, also affects dogs, 
which are considered the main reservoir for human infections (zoonotic VL, ZVL)1,6,7. Canine leishmaniasis 
affects animals of both sexes, all ages and breeds and the clinical course is generally chronic. Thus, L. infantum 
constitutes an important issue in both public health and veterinary medicine. In humans the highest prevalence 
and worst prognosis of ZVL are found in children, elderly and individuals with non-efficient immune system 
(e.g. HIV+ and other concurrent infections, immunodepressed recipients of solid organ  transplants8,9 or systemic 
lupus erythematosus–SLE-patients). In areas where ZVL is endemic, human infections by L. infantum are not 
very frequent, but the prevalence of canine infections in Europe can occasionally reach over 30%10; and in South 
America there are millions of dogs currently infected. Consequently, any control measure to limit the extension 
of human disease must necessarily include the control of canine leishmaniasis. Unfortunately, chemotherapy has 
serious shortcomings (e.g. low efficacy, high price of drug presentations of reduced toxicity)11, environmental 
prophylaxis is impracticable and available veterinary vaccines need substantial  improvements12.
Immune regulation of leishmaniasis has been extensively  analyzed13 in mouse models of VL. Susceptibility 
has been associated with a Th2 polarized response with production of  IgG1 and IgE, whereas resistant mouse 
lines are able to mount a Th1-based response with production of specific  IgG2a14. The Th1/Th2 framework, with 
the dichotomy leading to the control or proliferation of Leishmania, although relatively well characterized in 
mice, with susceptible and refractory strains, is clearly an oversimplification, and fundamental roles of Treg 
and some cytokines have been described in the tuning of Leishmania-host  interface15. The immune response in 
mice to L. infantum (or L. donovani) has little predictive value as to the response in humans, in which the Th1/
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Th2 polarization is far from  clear16. In the case of L. infantum, dogs are also natural hosts for the trypanosoma-
tid and the interest on the response elicited, both for diagnosis, prognosis or vaccination, has fueled research. 
Consequently, many reports on the cellular and humoral response and the cell types and cytokines involved 
have been published. Generally, resistance in canine leishmaniasis has been associated to upregulation of the 
Th1-cytokines (IFN-γ, TNF-α) with a significant cellular response; on the contrary, progression of the disease 
would be linked to a Th2-biased response (e.g. IL-4) with high production of  IgG17. It is well established that 
leishmaniasis in dogs is characterized by the limited cellular response and the high levels of antibodies (Ab), 
particularly  IgG18–23. However, reports on the IgG subclasses involved and their correlation to the clinical status 
of the infected animals are confusing. Thus, several studies have linked the active disease to a predominant  IgG1 
 response24–28 whereas in other reports it has been associated to a significant  IgG229–36 or a mixed  response20,37–39 
despite using comparable techniques and reagents.
Purification, identification and production of monoclonal antibodies (MAb) against the canine IgG subclasses 
 (IgG1,  IgG2,  IgG3,  IgG4)40–42 has allowed their comparison with marketed secondary antibodies (anti dog  IgG1 
and  IgG2). Their use in the study on several dog diseases, including  ZVL43, has highlighted the potential bias in 
the published reports on the IgG subclasses in  ZVL44. Despite the elapsed time since those results were obtained 
(> 10 years), very few studies using MAb specific for canine IgG subclasses have been  published45–48, whereas 
many contributions using commercial nonspecific immunological reagents have been published  afterwards28,33,35. 
This is most critical since the inaccurate determination of the immune scenario (cytokines, cells and immuno-
globulins, particularly IgG subclasses) in canine resistance, resilience or susceptibility is a strong shortcoming 
to develop vaccines or to assess the efficacy of chemotherapy or immunotherapy. In our case, the availability of 
sera from a large number of dogs subjected to an experimental infection with a recently isolated wild strain of L. 
infantum49 allowed us to determine the dynamics of production of specific IgG subclasses and their relationship 
to the clinical course of the experimental animals.
Results
Specificity of MAb anti‑IgG subclasses. Since no purified canine IgG subclasses were available, speci-
ficity of MAb (B6, E5, A3G4, A5) was assessed by capture ELISA. MAb A5 (anti-IgG4) reacted only with the 
serum captured by itself as coating Ab, thus confirming its specificity for dog  IgG4 (Table 1). Preliminary tri-
als performed with biotinylated MAb E5 (anti-IgG2) yielded inconsistent results. Therefore, its determination 
required the use of peroxidase-labeled anti-mouse  IgG2b. With this approach E5 reacted with the serum captured 
by itself besides showing nonspecific recognition of anti-IgG3. The cross-reactivity observed was expected since 
both the revealing labeled Ab (E5, anti-IgG2) and the coating anti-dog  IgG3 MAb (A3G4) were of mouse  IgG2b 
isotype. Interestingly, A3G4 showed a strong self-recognition (anti-IgG3) and lower reactivity with the serum 
captured by B6 (anti-IgG1). MAb B6 (anti-IgG1), employed as secondary (detection) Ab, slightly reacted when 
the coating MAb was itself (anti-IgG1) whereas it strongly reacted with dog serum captured by A3G4 (anti-IgG3). 
These results with capture ELISA confirmed that MAb recognized the four canine IgG subclasses. Therefore, 
they could be used to determine the dynamics of IgG subclasses. However, MAb displayed variable affinities and 
their value had to be confirmed in the indirect ELISA determinations in the infected dogs along the infection 
with L. infantum.
Experimental L. infantum infection in dog elicits the elevation of all IgG subclasses determined 
by ELISA. ELISA results indicated that inoculated Beagles showed an increase of all anti-L. infantum IgG 
subclasses related to the infection while the uninfected control dogs remained under the cut-off value during 
the experimental period. However, increase over pre-infection levels varied among IgG subclasses (Fig. 1A–D). 
Thus, while on week 7 post infection (pi), 30% (6/20) of the animals were already positive with total IgG,  IgG1, 
the most abundant subclass was only elevated in 3/20 dogs and  IgG2 and  IgG3 levels were over the cut-off value 
in 5% and 10% of the animals, respectively. Specific  IgG4 response was delayed and it was detected only from 
week 10 pi (7/20, 35%) onwards. At this sampling time (week 10 pi) 95% of the dogs (19/20) were IgG and  IgG1 
positive. Considering all the serum samples only 14 out of 20 infected dogs showed detectable levels of anti-
Leishmania  IgG4, and less than half of the animals displayed positive  IgG3 reactions (40%, 8/20) (Fig. 2A). All 
dogs, except #24, were anti-Leishmania  IgG2 positive at some sampling along the infection.
Table 1.  Summary of reactivity of monoclonal antibodies (MAb) against canine IgG subclasses in the 
specificity test carried out with capture ELISA. High (+++), moderate (++) and mild (+) reactivity. In brackets, 















B6  + –  + + –
E5 –  + + + – –
A3G4  + + +  + + +  + + + –
A5 – – –  + + + 
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Figure 1.  Serum anti-Leishmania IgG subclasses of Beagle dogs experimentally infected with L. infantum 
estimated by ELISA and flow cytometry and subclass-specific monoclonal antibodies (MAb). ELISA [(A)  IgG1; 
(B)  IgG2; (C)  IgG3; (D)  IgG4] assay was carried out with soluble leishmanial antigen and results are expressed as 
% of the positive control sera. Flow cytometry (FACS) [(E)  IgG1; (F)  IgG2; (G)  IgG3; (H)  IgG4] was performed 
with whole promastigotes. Solid circles: inoculated animals; empty circles: non-inoculated control dogs. Dotted 
line: cut-off level (%). Figure was prepared with GraphPad Prism 6.01 software.
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Average values of total IgG and IgG subclasses increased in a time-dependent manner despite the indi-
vidual variations (Fig. 2B). Specific anti-Leishmania IgG levels strongly correlated with  IgG1 (r = 0.9438),  IgG2 
(r = 0.8558) and  IgG4 (r = 0.7152) (P < 0.0001) but not with  IgG3 (r = 0.2961; P = 0.0010). Accordingly, whereas 
 IgG1,  IgG2 and  IgG4 were highly correlated (r = 0.7155–0.8441; P < 0.0001) no clear relationship emerged with 
 IgG3 (r = 0.250–0.269; P < 0.01). Considering the cumulative Ab response, estimated by the trapezoidal method 
(AUC), IgG levels up to week 16 pi strongly correlated with  IgG1 and  IgG2 but not with the other subclasses.  IgG2 
correlated with  IgG1 and  IgG4 but not with  IgG3 (Table 2).
Given the wide variation found in the immune response, levels of Ab were compared to the clinical score 
(CS) of the experimental dogs (Supporting Information Table 1). No correlation was found between Ab response 
and the clinical status in the early phases of the infection (5 weeks pi). However,  IgG1 and  IgG2 were positively 
Figure 2.  Positive dogs (above cut-off) (% of inoculated animals) and relative increase of anti-Leishmania 
serum IgG subclasses (% over pre-infection levels) of Beagle dogs experimentally infected with L. infantum. 
(A) Dogs positive by ELISA (IgG,  IgG1,  IgG2,  IgG3 and  IgG4); (B) Relative increase of specific IgG and IgG 
subclasses; (C) Dogs positive by flow cytometry (FACS) (IgG,  IgG1,  IgG2,  IgG3 and  IgG4); (D) Relative increase 
of specific IgG and IgG subclasses. ELISA was performed with leishmanial soluble antigen and FACS was carried 
out with whole promastigotes. Values of antibody increase by ELISA (B) and FACS (D) are mean ± standard 
error. Figure was prepared with GraphPad Prism 6.01 software.
Table 2.  Correlation (Spearman ρ value) between the cumulative Ab response of IgG subclasses along the 
experimental infection of dogs (16 weeks) with L. infantum. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns: not 
significant.
IgG IgG1 IgG2 IgG3 IgG4
IgG – 0.8511**** 0.6150** ns ns
IgG1 0.8511**** – 0.7008*** ns ns
IgG2 0.6150** 0.7008*** – ns 0.6271**
IgG3 ns ns ns – ns
IgG4 ns ns 0.6271** ns –
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correlated with the value of CS of experimental Beagle dogs on week 10 pi, and  IgG1 also on week 16th.  IgG2:IgG1 
and  IgG3:IgG1 ratios did not significantly vary with the clinical status of the animals but the  IgG4:IgG1 ratio 
showed a negative correlation with CS from week 10 pi onwards (Table 3).
Flow cytometry determination of specific IgG subclasses against L. infantum in experimen‑
tally infected dogs. MAb allowed the detection of the four IgG subclasses produced against L. infantum 
using flow cytometry. All inoculated animals were IgG and  IgG1 positive (over cut-off value) at some moment 
of the infection whereas six dogs did not show any detectable specific  IgG2 and in one dog no specific  IgG3 and 
 IgG4 were found (Fig. 1E–H). FACS-estimated response against L. infantum showed a steady time-dependent 
increase of specific IgG subclasses, besides total IgG. An early response of  IgG1 was found and by week 5 pi 55% 
(11/20) of the infected Beagles were positive, whereas response of other subclasses was low  (IgG3 and  IgG4, 5% 
of the animals) or absent  (IgG2) in this sampling time (Fig. 2C). This late response of  IgG2 was also evident by 
week 7 pi, when 80% of the inoculated dogs were positive to  IgG1 and only 2 out of 20 animals had  IgG2 levels 
over the cut-off value. Contrary to findings in ELISA, relative increase of  IgG4 was higher than that from  IgG3 
and  IgG2 (Fig. 2D). Moreover, in a similar way to that found with ELISA, the widest variation among inocu-
lated dogs was observed in specific  IgG4 response; values in the last sampling of some dogs experienced > 200% 
increase. Concentration of IgG subclasses determined by flow cytometry were correlated among them and with 
total IgG (r = 0.8245–0.9405; P < 0.0001) but no relationship between their levels and the CS of the dogs was 
observed. FACS values were correlated with ELISA values, particularly for total IgG (r = 0.8427; P < 0.0001) and 
 IgG1 (r = 0.8399; P < 0.0001). Other subclasses also showed significant correlations (P < 0.0001) but with lower “r” 
values  (IgG2: 0.7234;  IgG4: 0.7001;  IgG3: 0.6161).
Discussion
Inoculation of age- and sex- matched Beagle dogs with amastigotes of a fresh canine isolate of L. infantum 
elicited, under our conditions, an infection in all of them, developing clinical signs and lesions compatible with 
leishmaniasis. Progression of the disease was accompanied by a steady increase of all specific IgG subclasses 
determined  (IgG1,  IgG2,  IgG3,  IgG4). These results do not support the polarized framework described in natural 
and experimental canine leishmaniasis with either a predominant  IgG124–28 or  IgG229–35,50 response in clinically 
affected dogs.
Several causes can account for the inconsistent findings on anti-Leishmania specific  IgG1 and  IgG2 response 
in ZVL, including the general absence of quantitative determinations of IgG and IgG subclasses and the variable 
experimental designs (e.g. infective dose, number of animals, epidemiological surveys), methodologies (e.g. 
ELISA, Western blot, antigen and antigen preparation). For sure these factors must play important roles but, in 
our view, at least two main reasons have hampered the determination of the relative value of  IgG1:IgG2 and its 
diagnostic and prognostic potential in ZVL. The first relates to the scarce available information on the real role 
of IgG subclasses in dogs and their relationship to that found in  mice14,44,51 or  hamsters52–54. The second, is linked 
to the lack of specificity of immunological determinations which, in turn, are dependent on the specificity of the 
reagents. Mazza and coworkers characterized and developed MAb against canine IgG  subclasses40–42. In our case 
purified canine IgG subclasses were not available, and the specificity of the MAb obtained from the hybridoma 
lines (B6: anti-IgG1; E5: anti-IgG2; A3G4: anti-IgG3; A5: anti-IgG4) could not be tested directly but rather by 
capture ELISA. A5 and E5 showed a good recognition of  IgG4 and  IgG2, respectively. The cross reactivity found 
in capture ELISA between  IgG2 and  IgG3 was expected as anti-mouse  IgG2b was employed for the amplification 
to detect E5 (anti-IgG2,  IgG2b). Cross reactivity between  IgG1 and  IgG3 with MAb B6, already reported, could be 
due to a prozone phenomenon or competition for epitopes. Serum  IgG1 concentration in healthy dogs is over 20 
fold that of  IgG3 (8.17 ± 0.95 mg/mL vs. 0.36 ± 0.43 mg/mL), and quantitative assays suggested that there was no 
simultaneous  reactivity41. We have not performed quantitative ELISA but no correlation (ρ) between the  IgG1 
and  IgG3 response against L. infantum was observed in our study (see below). Thus, despite some shortcomings, 
the available MAb could be used to evaluate canine IgG subclasses along the experimental infection.
Our results show that the concentrations of all IgG subclasses were increased along the experimental infection 
with L. infantum in a time-dependent manner. This elevation of the four subclasses confirms and extends the 
results obtained with the same MAb by other  authors43,45–48. Response was variable among experimental dogs. 
 IgG1 and  IgG2, the most abundant subclasses, were also the dominant ones reacting in ELISA with leishmanial 
soluble antigen (SLA). Up regulation of specific  IgG1,  IgG4 and  IgG3, compared to  IgG2, has been reported in natu-
rally infected  dogs43,46. In our case, all inoculated animals developed clinical signs, lesions and biopathological 
Table 3.  Correlation (Spearman ρ value) between serum concentration of IgG subclasses and ratios, and the 
clinical score (CS) of dogs infected with L. infantum, at different pi times. wpi: weeks post inoculation. ns: not 
significant. *P < 0.05; **P < 0.01; ***P < 0.001.
Time IgG1 IgG2 IgG3 IgG4 IgG2:IgG1 IgG3:IgG1 IgG4:IgG1
5 wpi ns ns ns ns ns ns ns
10 wpi 0.6599** 0.7281*** ns ns ns ns − 0.5227*
14 wpi ns ns ns ns ns ns − 0.5070*
16 wpi 0.5102* ns ns ns ns ns − 0.5163*
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alterations compatible with leishmaniasis and L. infantum infection was confirmed by biopsy. ELISA results 
showed that the highest relative increase over pre-infection values corresponded to specific  IgG1 (over 100% after 
10 weeks of infection) followed by  IgG2 > IgG3 > IgG4 (Fig. 2B). The early increase of  IgG1 (95% positive on week 
10 pi) (Fig. 2A) suggests that, using ELISA and SLA as antigen, it could be a serum marker of active (recent) L. 
infantum infections whereas that of  IgG2 would indicate a more advanced infection. The  IgG4:IgG1 ratio was a 
good marker of the clinical course although the limited functional characterization of canine IgG  subclasses51 
and the lack of stoichiometry in our indirect ELISA preclude any speculation before more studies are performed.
The determination of IgG response to L. infantum using flow cytometry is less common, although some 
studies have been carried  out55. Given the lack of subclass specificity of marketed Ab, the apparently different 
response found in vaccinated dogs with Leishvaccine  (IgG1) or Leishmune  (IgG2) must be taken  cautiously56. 
Our results with FACS showed a general pi time-related increase of all subclasses and ELISA and flow cytometry 
values were correlated. This supports the value of the MAb for both assays and the consistency of the immune 
response, although  IgG1 was detected earlier by cytometry. Earlier  IgG1 response detected by FACS could be 
compatible with the recognition of membrane-bound antigen (Ag) and hence its potential value as infection 
marker. Interestingly, no correlation was found, at any sampling point, between the clinical score (CS) and 
IgG subclasses pattern. Contrarily to the ELISA results, the relative increase of  IgG4 along the follow-up was 
higher than that of  IgG2 and  IgG3 (Fig. 2D);  IgG4 values of experimental dogs (12 wpi) were also higher (ca. two 
fold) than those determined in dogs with chronic infection. Results seem factual and the possible significance 
(significance in acute phase, chronic phase) of the high relative levels of anti-Leishmania  IgG4 requires further 
research. The differential reactivity found in ELISA and FACS points towards variable sets of Ag being exposed 
and detected by the techniques and their degree of denaturalization (SLA vs. promastigotes). Scarce reactivity of 
 IgG2 with FACS, compared to ELISA, suggests that target Ag for  IgG2 response should be intracellular (soluble/
cytosolic). Further analyses with individual Ag (purified, WB) could confirm this hypothesis.
Results found in the follow-up of experimentally infected dogs with L. infantum support that the mouse-
based Th1  (IgG2a: resistance)/Th2  (IgG1: susceptibility) framework does not represent the actual events in canine 
leishmaniasis. Marketed anti-IgG1 and anti-IgG2 are not specific of dog IgG  subclasses43,44,48 and it is very likely 
that variable and inconsistent results obtained with  them28,33,35,57 could be biased.
Our study was carried out under controlled conditions and dogs were exposed to a single infection whereas 
under field conditions polyparasitism (along with other pathogens) is the rule. Moreover, animals were geneti-
cally close, the infective dose was very high, with amastigotes inoculated by IV route. The experimental design 
was efficient achieving well established infections but these factors could affect the immune response elicited, 
particularly in the early phases of parasite dissemination. Therefore, further research is needed to confirm our 
findings in naturally-acquired infections and dog breeds.
Despite these limitations, we can conclude that MAb employed allowed the detection of specific canine IgG 
subclasses against L. infantum by ELISA or cytometry. Cross reactivity found between MAb recognizing  IgG1 
and  IgG3 in capture ELISA possibly is not highly significant given their differential abundance in serum (ca. 
20 fold) and the different patterns found for both subclasses along the experimental infection. The concentra-
tions of all subclasses were increased after inoculation and  IgG1 was the predominant Ab and also the earliest to 
 appear45. Differential subclasses pattern found with ELISA and FACS and the lack of correlation between CS and 
FACS-determined response could be related to the different antigen sets and epitopes detected. Careful analyses 
of these Ag could give significant clues on the role of IgG subclasses in infected animals. This is critical to get an 
accurate picture of the immune events in ZVL and could facilitate the diagnosis and prognosis of the disease as 
well as provide a useful tool for better therapeutics and vaccine development.
Material and methods
Leishmania infantum strain. L. infantum strain was obtained from the spleen of a naturally infected dog 
from southern Spain (Órgiva, Granada), clinically and serologically diagnosed. Details on the isolation of para-
sites to inoculate the dogs have been previously  published49. Briefly, the spleen was cut into small pieces and 
homogenized in a glass-in-glass tissue grinder. Suspensions were centrifuged and cell pellets were treated with 
cell lysis buffer. Isolation was performed under sterile conditions and amastigotes were kept at 4 °C for 24 h 
and used to inoculate dogs. The isolate was characterized (MCAN/ES/2016/Granada-UCM) using published 
kinetoplast primers and by a specific PCR-hybridization-ELISA with a cloned 196 bp of L. infantum kDNA58,59.
Experimental infection of dogs with L. infantum and follow‑up. Dogs (24 female Beagles) were 
obtained when they were 4–5 months old (Envigo, France) and housed at the animal facility Nr ES280790000091 
of the Faculty of Veterinary Medicine UCM (Madrid). Details of the housing, inoculation and follow-up of the 
experimental animals have been previously  published49. Briefly, when the animals reached 10–11 months age, 
20 were inoculated (cephalic vein) with  108 amastigotes of L. infantum/animal, in 1 mL. Four animals were kept 
as uninfected control dogs. Blood samples were obtained before infection and on weeks 5, 7, 10, 12, 14 and 16 
post inoculation (pi) to perform biopathological and immunological determinations. Dogs were observed daily 
and subjected to complete clinical examination by a veterinarian blinded to the experimental design. Follow up 
included IFAT and infection status of the animals on week 16th pi by popliteal lymph node biopsy. Clinical scor-
ing (CS) of the animals (Suplementary Information) included clinical signs and lesions, and biochemical and 
hematological abnormalities, and was determined following a previous  publication49.
Monoclonal antibodies (MAb). Hybridoma lines. Frozen hybridoma lines secreting mouse MAb against 
dog  IgG1 (B6),  IgG2 (E5),  IgG3 (A3G4) and  IgG4 (A5)40–42 were supplied by Ms. S. Holt (Veterinary Faculty, Bris-
tol, UK). Hybridoma lines were thawed and cultured at 37 ºC in RPMI-1640 medium (BioWhittaker, Lonza) 
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supplemented with 10% heat inactivated fetal calf serum, 1% l-Glutamine 200 mM (BioWhittaker, Lonza), and 
100 U/mL penicillin plus 100 μg/mL streptomycin (BioWhittaker, Lonza). Several subcultures were performed 
to obtain supernatants.
Isotyping of MAb was carried out by capture ELISA. Briefly, 96-well high binding microtiter plates (NUNC, 
Thermo Fisher) were coated with 3 μg/mL (50 µL/well) of goat polyclonal anti-mouse IgG (SouthernBiotech) in 
 HCO3−/CO3− (0.1 M pH 9.7), overnight at 4 ºC. After blocking (2% BSA, 75 μL/well, 30 min, 37 ºC) and three 
washes with PBS-Tween, supernatants from hybridoma cultures (8 replica/hybridoma line) were added (50 μL/
well) and incubated at 37 ºC, 2 h. Plates were washed as above and peroxidase labeled antibody (Ab) against 
murine isotypes (SouthernBiotech) and light chains were added: anti-IgA, anti-IgM, anti-IgG1, anti-IgG2a, anti-
IgG2b, anti-IgG3, anti-kappa and anti-lambda at 1/2000 dilution and incubated at room temperature (RT) for 
30 min. Plates were extensively washed (5×) and color reaction was developed with 100 μL/well OPD (1 mg/
mL) in citrate–phosphate buffer (0.1 M citric acid-0.2 M sodium phosphate, pH 5.3) with hydrogen peroxide 
(1/1000). Reaction was stopped with  H2SO4 3 N (50 μL) and absorbance read at 492 nm with Varioskan LUX 
(Thermo Fisher Scientific). It was confirmed that hybridoma lines B6 and A5 secreted  IgG1-kappa Ab whereas 
 IgG2b-kappa Ab were produced by lines E5 and A3G4.
Purification of MAb. Prefiltered supernatants (SFCA 0.2 µm, Corning) from hybridoma cultures were immu-
noadsorbed to a protein column (HiTrap 1 mL Protein G HP, GE Healthcare) with peristaltic pump EP-1 Econo 
Pump (BioRad) and a flow of 1.5 mL/min. Column was washed (PBS, pH 7.2) and bound Ab were eluted with 
 NH4OH 0.5 N. Fractions (ca. 0.5 mL) with significant protein concentration (280 nm, spectrophotometer Smart-
Spec Plus, BioRad) were dialyzed against PBS in a visking tube of 12–14 KDa (Medicell Membranes Ltd) for 24 h, 
at 4 ºC, three changes, and the final concentration was determined with the RC-DC Protein Assay kit (BioRad).
Labeling of MAb and specificity. Purified MAb were labeled with biotin (EZ-Link Sulpho-NHS-LC-Biotin, 
Thermo Fisher) using manufacturer’s indications with minor modifications. Efficacy of labeling was assessed 
by indirect ELISA using total dog IgG purified as above to coat microtiter plates (10 µg/mL; 50 µL/well). After 
blocking (BSA 2%, 30 min, 37 ºC) biotin-labeled MAb were added (50 μL/well) and serially diluted in PBS-
BSA-Tween (PBS-BSA-T), 1  h, RT. Reaction was developed with 50 μL/well peroxidase-labeled streptavidin 
(Streptavidin-HRP, SouthernBiotech) 1/2000 in PBS (30  min, RT) and color development was quantified as 
above (see isotyping). All MAb were positive, except E5 (anti-IgG2) despite re-labeling with double concentra-
tion of  biotin60.
Specificity of MAb was assessed by capture ELISA using 2.5 µg/mL MAb to coat microplates. Serum from a 
healthy dog was added (1/200, 1 h, 37 ºC) and rabbit serum was used as negative control. Biotin-labeled MAb 
(B6, A3G4, A5) were used at 1/400, and unlabeled MAb (E5) at 1 µg/mL (1 h, RT). MAb peroxidase-streptavidin 
(SouthernBiotech), and for E5, peroxidase-labeled anti-mouse  IgG2b (SouthernBiotech) (1/2000, 30 min, RT) 
were used to detect Ab reactivity.
Anti‑Leishmania IgG subclasses of experimentally infected dogs determined by ELISA. Pro-
cedures to propagate promastigotes by back transformation of amastigotes from the original isolate and to 
obtain soluble leishmanial antigen (SLA) have been described  previously49. Briefly, promastigotes were cultured 
in RPMI 1640 medium, supplemented with antibiotic–antimycotic mixture (BioWhittaker), l-glutamine (Bio-
Whittaker), 10% fetal calf serum (Gibco) and human urine (1%). SLA was obtained by centrifugation of mid-log 
phase promastigotes subjected to freezing-and-thawing cycles.
Levels of specific IgG and subclasses in the infected dogs were determined by indirect ELISA using as positive 
control the serum from a dog with an immunologically and parasitologically confirmed chronic natural infection 
by L. infantum; negative control serum came from a healthy dog. Microplates were coated with 10 μg/mL SLA 
(50 μL/well) overnight at 4 ºC. After blocking (2% BSA, 30 min), dog sera were added (50 μL/well) at 1/400 (total 
IgG), 1/100  (IgG1,  IgG3 and  IgG4) or 1/50  (IgG2) in PBS-BSA-T (1 h, 37 ºC). Biotinylated secondary Ab anti-IgG1 
(MAb B6), anti-IgG3 (MAb A3G4) and anti-IgG4 (MAb A5) were used at 1/500, 1/1000 and 1/1000, respectively, 
in PBS-BSA-T (50 μL/well) (1 h, RT). Unlabeled MAb (E5, anti-IgG2) was used at a concentration of 1 µg/mL 
and was incubated at 37 ºC. Secondary polyclonal anti-IgG (goat anti-Dog IgG H + L-HRP, Bethyl Laboratories, 
Cat. No. A40-123P) was used at 1/2000 in PBS-BSA-T (30 min, RT). Biotinylated MAb were detected with 
HRP-labeled streptavidin (SouthernBiotech), 1/2000 in PBS-BSA-T (50 μL/well, 30 min, RT). For the unlabeled 
MAb (anti-IgG2), peroxidase-labeled anti-mouse (goat anti-Mouse  IgG2b, Human ads-HRP, SouthernBiotech, 
Cat. No. 1090-05) was employed using the same conditions. Color was developed and OD read as above. Results 
were expressed as % of the positive control sera (OD of the sample/OD positive control × 100). Mean % OD + 3 
standard deviations—SD—of the pre-infection values was used as the cut-off value. Relative increases (%) over 
pre-infection values were also estimated.
Determination of anti‑Leishmania IgG subclasses by flow cytometry (FACS). The same negative 
and positive controls used for ELISA were employed in the evaluation of total IgG and IgG subclasses. Mid-log 
phase promastigotes of the homologous isolate of L. infantum were diluted in PBS (5 × 108cells/mL) and divided 
in 50 μL aliquots in 1.5 mL Eppendorf tubes. An equal volume of serum was added for each experimental ani-
mal and sampling time. Tubes were kept ice-cooled for 1 h and reaction was stopped by adding 1 mL/tube 1% 
formaldehyde in PBS. Contents of the eppendorf tubes was divided onto 5 tubes (200 μL/tube), replenished with 
BD FACSFlow buffer and centrifuged (15,000×g, 1 min). Cell pellets were resuspended in 100 μL of PBS contain-
ing 1 μg/mL from each unlabeled MAb, incubated (1 h, RT), washed with FACSFlow and centrifuged (15,000×g, 
1 min). Anti-mouse fluorescein labeled Ab (Alexa Fluor 488-conjugated AffiniPure Goat Anti-Mouse IgG, Fcγ 
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Fragment Specific, Jackson ImmunoResearch, Cat. No. 115-545-008) was added at 1/500 (100 μL/tube). To 
determine total IgG, cells were resuspended with fluorescein labeled anti-IgG (FITC-conjugated AffiniPure Rab-
bit anti-Dog IgG H + L, Jackson ImmunoResearch, Cat. No. 304-095-003) (100 μL/tube) at 1/100. All tubes were 
incubated (in the dark, 30 min, RT), washed and their contents transferred onto 5 mL cytometry tubes (Corning 
Falcon) using FACSFlow buffer to get 0.5–1 mL/tube. Cellular analysis was performed with a flow cytometer 
BD FACSCalibur (Becton Dickinson) and the programme CellQuest Pro v4.0.2. Fluorescent cells were counted 
(10,000 events, FL-1 filter) and results, mean fluorescence intensity (MFI), were expressed as above (see ELISA).
Ethics. The experimental protocol followed the legislation of the European Commission (Directive 63/2010/
UE) and Spanish transposition (Royal Decree 53/2013) and the 3Rs guidelines. Design and procedures were 
approved by the Ethical Committee of the Veterinary Faculty (CEEA VET), UCM committee for animal experi-
mentation and the Comunidad de Madrid Regional Government (Ref. PROEX 329/15). All personnel in direct 
contact with the animals were officially qualified for animal experimentation (ECC/566/2015).
Statistical analysis. ELISA values were expressed as percentage (%) of the OD value found for the positive 
control serum (OD of samples/ average OD of positive control × 100); and as relative increase (%) over pre-
infection OD values. FACS values were expressed the same way but employing MFI. Cumulative Ab response 
was estimated using the trapezoidal method to determine areas under the curve (AUC) of each animal from 
pre-infection to 16 weeks pi point. Relationship between the different subclass levels or the different techniques, 
as well as between CS and subclass levels (with different techniques), were evaluated using the non-parametric 
Spearman correlation. In all statistical analyses, the level of significance was set at P < 0.05. Figures and statistical 
analysis were performed using GraphPad Prism 6.01 software.
Data availability
All data generated or analyzed during this study are included in this published article.
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